[Antibacterial activity in vitro of a new rifamycin: rifamide].
D004352:Drug Resistance, Microbial; D004755:Enterobacteriaceae / Q000187:drug effects*; D013293:Enterococcus faecalis / Q000187:drug effects; D004917:Erythromycin / Q000494:pharmacology; D004926:Escherichia coli / Q000187:drug effects; D007709:Klebsiella / Q000187:drug effects; D008034:Lincomycin / Q000494:pharmacology; D011511:Proteus / Q000187:drug effects; D011549:Pseudomonas / Q000187:drug effects; D012293:Rifampin / Q000494:pharmacology*; D012475:Salmonella / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects*; D013291:Streptococcus / Q000187:drug effects*; D013297:Streptococcus pyogenes / Q000187:drug effects; D013752:Tetracycline / Q000494:pharmacology
D004917:Erythromycin; D008034:Lincomycin; D013752:Tetracycline; D012293:Rifampin
Activité antibactérienne "in vitro" d'une nouvelle rifamycine: la rifamide.